Organization
Radboud University Medical Center and Radboud Institute for Molecular Life Sciences
14 abstracts
1 poster
Abstract
A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia.Org: City of Hope National Medical Center, Erasmus University Medical Center, Institut Paoli-Calmettes, Marseille, France, University Medical Center Groningen, MD Anderson Cancer Center,
Abstract
Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after ten year follow-up.Org: Biometrics Department, Department of Gynecological Oncology, Sint Antonius Hospital, Department of Gynecology and Obstetrics, Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, IOV - Istituto Oncologico Veneto IRCCS -IOV,
Abstract
Primary outcome analysis of the ORCHESTRA trial: A randomized phase III trial of additional tumor debulking to first-line palliative systemic therapy for patients with multiorgan metastatic colorectal cancer.Org: Radboud UMC, Erasmus Medical Center, Radboud University Medical Center and Radboud Institute for Molecular Life Sciences, Amsterdam UMC location VUMC, Erasmus MC Cancer Institute,
Abstract
Clinical efficacy and biomarker analysis of pre-operative ipilimumab plus nivolumab in stage III urothelial cancer: The NABUCCO trial update.Org: Netherlands Cancer Institute, Radboud University Medical Center and Radboud Institute for Molecular Life Sciences, University Medical Center Utrecht,
Abstract
Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: Propensity score–matched recurrence-free, distant metastasis-free, and overall survival analysis.Org: Leiden University Medical Center, Maastricht University Medical Centre, Zuyderland MC, The Netherlands Cancer Institute, University Medical Center of Utrecht,
Abstract
Debio 0123-101: A phase 1 trial of Debio 0123 in combination with carboplatin in advanced solid tumors—Safety, pharmacokinetic, and preliminary antitumor activity data.Org: Leiden University Medical Center, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, University Medical Center Groningen, Radboud University Medical Center and Radboud Institute for Molecular Life Sciences, Vall d'Hebron Institute of Oncology,
Abstract
177Lu-PSMA radioligand therapy for recurrent/metastatic (R/M) salivary gland cancer (SGC) patients: A phase II pilot study.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Radboud University Medical Center and Radboud Institute for Molecular Life Sciences, Radboudumc,
Abstract
Upfront palliative resection of primary tumor versus no resection in patients with synchronous metastatic colorectal cancer: The randomized phase 3 CAIRO4 study of the Dutch Colorectal Cancer Group (DCCG).Org: University Medical Center Utrecht, Utrecht University, Netherlands Comprehensive Cancer Organisation (IKNL), Erasmus Medical Center, Amsterdam University Medical Centers,
Abstract
Ex vivo tumor testing platform for predicting clinical response to platinum-based therapy in patients with high grade serous ovarian cancer.Org: Radboud University Medical Center and Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands Cancer Institute, Leiden University Medical Center, Leiden University,
Abstract
Patient-reported symptom monitoring linked to an alert algorithm: Effects on progression-free and overall survival in the SYMPRO-Lung trial.Org: Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands, Netherlands Comprehensive Cancer Organisation (IKNL), The Netherlands Cancer Institute, Radboud University Medical Center and Radboud Institute for Molecular Life Sciences,
Abstract
A prediction model for response to immune checkpoint inhibition in advanced melanoma.Org: University Medical Center Utrecht, Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands, VU University Medical Center, Isala Oncology Center, University Medical Center of Utrecht,
Abstract
Survival in patients with unresectable melanoma: To infinity and beyond?Org: University Medical Center of Utrecht, Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands, VU University Medical Center, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital/Netherlands Cancer Institute,
Abstract
AN EHEALTH TOOL TO PREPARE A FIRST ORTHOPAEDIC CONSULTATIONS: A USE AND USABILITY STUDYOrg: Sint Maartenskliniek, Leiden University Medical Center (LUMC), Leiden, Netherlands, Radboud University Medical Center and Radboud Institute for Molecular Life Sciences,
Abstract
BELIEFS ABOUT URATE LOWERING THERAPY DIFFER BETWEEN GENERAL PRACTITIONERS AND RHEUMATOLOGISTSOrg: Sint Maartenskliniek, Radboud University Medical Center and Radboud Institute for Molecular Life Sciences,